Expedition Therapeutics

Expedition Therapeutics develops treatments for inflammatory and respiratory diseases, led by EXPD-101, a next-generation oral DPP1 inhibitor engineered to selectively block activation of neutrophil serine proteases. The program is a potent, oral, once-daily DPP1 inhibitor being developed for COPD, with additional indication expansion potential in bronchiectasis, neutrophilic asthma and other neutrophil-driven diseases.

Current COPD therapies manage symptoms without addressing the chronic neutrophilic inflammation that drives disease progression, and benefit remains limited among patients with non-type 2 disease. EXPD-101 directly targets neutrophilic inflammation, one of the major mechanisms driving COPD, without compromising neutrophil host surveillance or depleting neutrophil counts. Expedition conducts the first global, randomized trial of a DPP1 inhibitor in COPD, aiming at an inflammatory pathway that the broader class of available COPD therapies does not directly act on.